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Objective: The present study was designed to evaluate the long-term efficacy and safety of once-daily enoxaparin plus
warfarin for the outpatient ambulatory treatment of lower-limb deep venous thrombosis (DVT).
Methods: A total of 246 patients, comprising 128 men (mean age, 54.28 16.48 years) and 118 women (mean age, 50.11
16.47 years) with symptomatic lower extremity DVT, were included in this open-label, single-arm, multicenter, phase IV
clinical trial conducted at 14 centers in Turkey. All patients were administered subcutaneous enoxaparin (1.5 mg/kg,
once-daily) until international normalized ratio (INR) levels reached to 2 to 3, followed by oral warfarin (5mg/d) for at least
3 months and elastic compression stockings (30-40 mm Hg). Clinical signs (leg circumference), symptoms (edema, pain,
tenderness), recanalization rates upon duplex ultrasound examination, laboratory findings (D-dimer and INR levels), and
postthrombotic syndrome status with CEAP classification were the efficacy parameters evaluated every 3 months during 18
months of follow-up. Safety end points included minor and major bleeding as well as serious adverse events.
Results: Ambulatory treatment with enoxaparin plus warfarin significantly reduced physical symptoms, including tenderness,
edema, pain (P < .001), and the circumference of the affected leg (P < .001). The leg circumference difference in almost all
patients was<1.5 cm at the end of 18 months (P< .001). Recanalization rates for occluded iliofemoral vein were 76.1% at 3
months and 86.5% at 18months (P< .001). An early and significant decrease obtained inD-dimer levels on day 10 continued
to decline significantly until month 6 and remained unchanged afterwards (P< .001). Of four patients diagnosed with major
bleeding during oral anticoagulant use, three recovered with conservative treatment (reduction in hemoglobin levels in 2
developed at visit 2 [day 10] and intracranial bleeding in 1 developed at visit 3 [day 30]), and one patient required a
hysterectomy after menorrhagia developed at visit 7 (month 18). Two of the 65 (9.9%) adverse events documented were
serious adverse events, but none of the serious adverse events leading to death were related to the study medications.
Conclusion: Ambulatory treatment with enoxaparin plus warfarin seems to be effective in symptomatic healing and in
clinical improvement by reducing thrombus formation and organization at all levels of lower extremity venous system
withDVT, without a significant major bleeding risk. Therefore, the results of our conventional conservative treatment are
in line with 1A level evidence reported in the recent American College of Chest Physicians guideline. ( J Vasc Surg 2010;
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1262Characterized by secondary complications including
pulmonary thromboembolism, chronic venous insuffi-
ciency (postthrombotic syndrome), chronic pulmonary hy-
pertension, and recurrent thrombosis,1,2 deep venous
thrombosis (DVT) of the lower limbs is a serious disorder
that leads to significantmorbidity andmortality.3,4 Numer-
ous studies and meta-analyses in the literature have con-
firmed that administration of low-molecular-weight hepa-
rins (LMWHs) for 5 to 10 days as a bridge to oral
anticoagulant therapy with vitamin K antagonists for at
least 3 months5,6 in the treatment of DVT is as safe and
efficient as conventional anticoagulation.3,7-9
Enoxaparin, an LMWH, has antithrombotic activity
comparable with and theoretically more predictable than
unfractionated heparin (UFH)10,11 and offers an alterna-
tive to in-hospital treatment that can be done at home,
owing to easy subcutaneous (s.c.) administration once or
twice daily, without routine monitoring.3 Such an option
allowing treatment of patients with DVT in an ambulatory
setting12 is considered to be cost-effective, reducing health
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comfortable for the patients by alleviating pain, improving
the quality of life, and lowering the rate of postthrombotic
syndrome.15,16
The American College of Chest Physicians (ACCP)
Evidence-Based Clinical Practice Guidelines on Anti-
thrombotic and Thrombolytic Therapy17 recommend that
patients with acute DVT receive an initial treatment with
LMWH (s.c. once or twice daily) for at least 5 days until
the international normalized ratio (INR) is 2.0 for 24
hours (grade 1C) as an outpatient therapy (grade 1C),
along with early ambulation in preference to initial bed
rest (grade 1A).
Although treatment of DVT at home with once-daily
or twice-daily doses of LMWH has been shown to be as
effective and safe as in-hospital intravenous UFH,9 few
studies have examined the long-term outcomes of a once-
daily regimen of LMWH given at home.18 Besides, recent
studies seem to focus on the superiority of thrombolytic
treatment compared with conventional measures based on
old literature stating postthrombotic syndrome rates of up
to 60% in case of conservative treatment,19 which indicated
the value of the follow-up with careful anticoagulation
lasting as long as possible compared with thrombolytic
treatment. However, long-term follow-up studies after
thrombolysis are necessary to determine whether improved
thrombus resolution translates to better functional out-
come and reduced postthrombotic morbidity.20-22 Al-
though the ACCP Consensus Conference Section stated
that “there is no evidence that supports the use of throm-
bolytic agents for the initial treatment of DVT,’’23 use of
stockings plus once-daily enoxaparin has been investigated
in only a limited number of recent studies.
Therefore, the present study aims to report the results
of the national, single-arm, prospective, multicenter, and
open-label TROMBOTEK trial designed to investigate the
long-term (18-month) efficacy and safety of once-daily
enoxaparin as a bridge to warfarin for the outpatient am-
bulatory treatment of lower-limb venous thromboembolism.
METHODS
Patient population. A total of 251 patients aged18
years and diagnosed with symptomatic acute lower extrem-
ity DVT by color duplex ultrasound (DUS) imaging,
whether or not accompanied by verified symptomatic pul-
monary emboli, and provoked or not with temporary risk
factors (eg, surgery) were enrolled in TROMBOTEK, an
open-label, single-arm, multicenter, phase IV clinical trial
conducted between December 2004 and September 2007
at 14 centers across Turkey.
Inclusion and exclusion criteria of the study are re-
ported in Table I. Written informed consent was obtained
from each participant after a detailed explanation of the
objectives and protocol of the study, which was approved
by the Institutional Ethics Committee and conducted in
accordance with the ethical principles stated in the Decla-
ration of Helsinki and International Conference on Har-
monisation of Technical Requirements for Registration ofPharmaceuticals for Human Use (ICH)/Good Clinical
Practice (GCP).
Study protocol. All patients included in the study
were administered enoxaparin (Clexane; Sanofi-Aventis,
Istanbul, Turkey; 1.5 mg/kg, once-daily s.c.) as a bridge to
oral anticoagulant warfarin treatment for at least 3 months.
Enoxaparin was continued until international normalized
ratio (INR) levels 2. In accordance with ACCP guide-
lines,17 all patients were provided with compression stock-
ings (30-40 mm Hg, class 2, Sigvaris 702; Ganzoni/Sig-
varis, Winterthurt, Switzerland) at the initial and 6-month
visits and advised to use them for at least 12 months. After
the initial visit on day 0 (visit 1), other visits were planned to
be performed on day 10 (visit 2) and day 30 (visit 3), and
then at 3 (visit 4), 6 (visit 5), 12 (visit 6), and 18 (visit 7)
months (Fig 1).
Primary efficacy parameters were the presence of DVT
at different levels of the lower venous system and change in
the frequency of DVT by means of study treatment and
presence of pulmonary embolism. Secondary short-term
efficacy parameters were difference in leg circumference
(measured at the level of midthigh and 5 cm below tuber-
ositas tibia),24 presence of edema (with Godet or general-
ized edema), presence of leg pain, laboratory assessment of
D-dimer levels (immunoturbidimetric assay by micropar-
Table I. Inclusion and exclusion criteria of the present
study
Inclusion criteria
● Symptomatic acute deep venous thrombosis and/or pulmo-
nary embolism confirmed by venous ultrasound imaging
and/or CT scan
● Pulmonary embolism patients with normal right ventricular
size on chest CT scan
● Age 18 years
● Anticipated discharge 72 hours of admission
Exclusion criteria
● Pregnancy or intend to become pregnant
● Patients requiring ongoing hospitalization 72 hours
● Hypersensitivity to heparin, pork products, or enoxaparin
● Creatinine 2.0 mg/dL
● Recurrent DVT and/or pulmonary embolism with oral anti-
coagulation
● Surgery or medical procedure planned during the study that
may pose a significant bleeding risk
● History of heparin-induced thrombocytopenia
● Inability to participate in follow-up appointments and study
visits
● Life expectancy 30 days
● High risk of bleeding:
– Active major bleeding 30 days by GUSTO criteria
– History of intracranial bleeding
– Major surgery or trauma within 10 days
– Head injury requiring hospitalization 1 year
– Intracranial tumor
– Neurosurgery or noncataract ophthalmologic surgery 1
month
– Thrombocytopenia
CT, Computed tomography; DVT, deep vein thrombosis; GUSTO, Global
Use of Strategies to Open Occluded Coronary Arteries.ticle antigen agglutination method with reference range
atio; P
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thrombus in lower venous system (DUS evaluation). All
laboratory investigations were performed at a core labora-
tory. Secondary long-term efficacy parameters were risk
factors and temporary risk factors for DVT, clinical proba-
bility of DVT, change in the DVT probability during
follow-up, determination of postthrombotic syndrome sta-
tus with symptoms, and change in the clinical (C) compo-
nent of the CEAP classification.25
Pain and tenderness were documented as “present or
not present.” Edema was assessed as the difference between
the circumference of the normal and thrombotic leg.
Thrombus localization (left vs right), compressibility ratio
(absent: 0-2 mm; reduced: 2-4 mm, or complete:4 mm),
recanalization ratio (total occlusion, 0%, 50%, 50%;
complete recanalization, 100%), peak systolic retrograde
reflux velocity (reflux rate 10 cm/s, 10-30 cm/s, 30 cm/s),
and reflux time 0.5 second were defined with DUS.
Sonographers at three centers performed DUS using a
color-flow duplex imager. Sonographers were trained be-
fore the study to standardize performance and were un-
aware of the results of the previous DUS results. The
following venous segments were evaluated for each patient:
common femoral, femoral (midthigh), popliteal, posterior
tibial, peroneal, gastrocnemius, soleus, and great saphe-
nous (thigh and calf).26
Safety end points included bleeding and serious adverse
events. Safety parameters were laboratory findings, includ-
ing complete blood count, alkaline phosphatase (ALP),
alanine transaminase (ALT), aspartate transaminase (AST),
bilirubin, creatinine kinase (CK), calcium and sodium lev-
els, and minor and major bleeding. Major bleeding was
defined as overt bleeding accompanied by one or more of
the following conditions:2-g/dL reduction in hemoglo-
bin level, at least 2 units of blood transfusion; retroperito-
neal, intracranial, or intraocular bleeding; need of medical
Fig 1. Study plan according to seven consecutive vis
computed tomography; INR, international normalized ror surgical intervention; or death. Minor bleeding wasconsidered as clinically diagnosed bleeding lacking major
bleeding criteria. Adverse events, spontaneously reported
by the patient or noted by the investigator, or both, were
recorded on all visits after the screening period.
Statistical analysis. Statistical analysis was made using
SPSS 13.0 software (SPSS Inc, Chicago, Ill). The effect of
treatment was compared with pretreatment data using the t
test for parametric variables and 2 and Fisher tests for the
categoric data. Efficacy and safety parameters were summa-
rized using descriptive statistics. Data were expressed as
mean  standard deviation and percentage (%), where
appropriate. P .05 was considered statistically significant.
RESULTS
Demographics and baseline clinical characteristics.
The study enrolled 251 patients, but 5 were withdrawn
because they received enoxaparin from the hospital phar-
macy instead of enoxaparin labeled as study drug. As a
result, the study was conducted with 246 patients compris-
ing 128 men (52%), who were a median age of 55 years
(range, 18-90 years; mean, 54.28  16.48), and 118
women (48%), who were a median age of 47 years (range,
18-81; mean, 50.11  16.47 years), diagnosed with lower
limb DVT who completed the 18 months of follow-up
including seven consecutive visits. Clinical probability of
DVT was determined to be high among 69.0% of patients
according to Wells Scoring. Most of the DVT was pro-
voked by immobility (51.4%), previous surgery (24.1%),
and previous major trauma (9.4%; Table II).
Efficacy. According to final analysis of the results,
DUS examinations showed a significant decrease in the
number of occluded veins with treatment. Complete recan-
alization ratios for occluded peripheral veins located in the
iliofemoral vein segment without caudad involvement were
86.5% for iliofemoral vein and 51.5% for external iliac vein.
At the end of 18months, the recanalization ratio was 70.5%
ithin 18 months. CBC, Complete blood count; CT,
T, prothrombin time; VTE, venous thromboembolism.its wfor common femoral vein and 39.2% for the femoral vein,
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 5 Kurtoglu et al 1265representing veins above knee but below the common
femoral vein; and 44.9% for the popliteal vein and 33.4% for
tibioperoneal veins, representing the veins located below
the knee (Table III).
Recanalization ratios for totally occluded iliofemoral
and common femoral veins were prominent at 18 months
compared with the initial values (P .001 for each; Fig 2).
The increase in peak retrograde reflux velocity was deter-
mined at visit 7 (18 months) compared with velocity levels
obtained on the initial visit (6.3% vs 26.1% for velocity of
10 cm/s; 3.9% vs 28.1% for velocity of 10-30 cm/s; and
1.2% vs 10.5% for velocity of 30 cm/s). Reflux time was
0.7 seconds (none) in 90.9% vs 35.3% of patients with
respect to measurements obtained on the first and last visit,
Table II. Patient demographics and medical history
Variable
No. (%) or
mean  SD
Sex
Male 128 (52.0)
Female 118 (48.0)
Age, y
Male 54.3  16.5
Female 50.1  16.5
Risk factors for VTE/temporary risk
factors
Immobility for a long period 126 (51.4)
Varicose veins 75 (30.6)
Previous surgery 59 (24.1)
Previous major trauma 23 (9.4)
Malignancy 19 (7.8)
Current use of oral estrogens 15 (6.1)
Acute exacerbation of acute
bronchitis 14 (5.7)
Chemotherapy or radiation therapy 9 (3.7)
Congestive heart failure 7 (2.9)
History of DVT 3 (1.2)
Acute exacerbation of rheumatic
disease 2 (0.8)
History of pulmonary thrombosis 1 (0.4)
Acute exacerbation of IBD 1 (0.4)
Detailed classification of clinical
probabilities
Presence of DVT 240 (97.5)
Active malignancy 12 (4.9)
Immobilization (plaster cast,
paralysis, or paresthesia) 19 (7.7)
Bed rest 3 days or major surgery
1 month 84 (34.2)
Tenderness on deep venous system 170 (69.1)
Edema on all leg 164 (66.7)
One-sided calf edema 168 (68.3)
Symptomatic leg edema with
Godet formation 127 (51.6)
Collaterals of superficial veins 64 (26.0)
Clinical probability of DVT (Wells
scoring)
High 169 (69.0)
Intermediate 71 (29.0)
Low 5 (2.0)
DVT, Deep vein thrombosis; IBD, inflammatory bowel disease; SD, stan-
dard deviation; VTE, venous thromboembolism.whereas a gradual increase in reflux was evident during thecourse of the study (4.7% vs 24.2% of patients for short-
term reflux and 4.3% vs 40.5% of patients for long-term
reflux).
Combined treatment with enoxaparin and add-on war-
farin was associated with a significant reduction in the
incidence of symptoms that are common to patients with
DVT, including tenderness (82.6% vs 4.8%), edema (95.5%
vs 48.3%), and pain (93.4% vs 16.3%) when pretreatment
and posttreatment rates were compared (P .001 for each;
Fig 3). Symptomatic healing concerning leg pain and ten-
derness was prominent as early as day 10 (compared with
day 1), improved significantly at all visits until day 30, and
persisted afterwards (P  .001 for each) until 18 months.
Decrease in edema symptoms, however, was prominent as
long as the third month of the follow-up (Fig 3).
The difference between the normal and thrombotic leg
in terms of circumference measured at 5 cm below the tibial
tuberosity (4.51  2.8 and 1.43  1.87 cm, respectively)
and midthigh circumference (4.91  3.9 and 1.22  2.2
cm, respectively) decreased significantly during the treat-
ment course (P .001 for each; Fig 3) beginning as early as
day 10 and persisted until 18 months (P  .001 for each;
Fig 4). The difference between the circumferences of the
normal and diseased leg decreased significantly to values
1.5 cm during long-term follow-up (Table IV).
Optimal INR levels were obtained within 7 to 10 days
of initiation of oral anticoagulant therapy. However, INR
levels were subtherapeutic in almost 20% of patients at all
visits (Fig 5).
An early and significant decrease was obtained in D-
dimer values (g/L) during the course of the study, from
3119.36 4468.91 (visit 1) to 1772.88 33124.79 (visit
2), 993.08  3045.60 (visit 3), 386.13  1227.48 (visit
4), 250.50  375.06 (visit 5), 291.59  441.24 (visit 6),
and finally, to 374.30 698.34 (visit 7; P .001 for each).
The percentage of patients with D dimer levels within the
normal reference range (150 g/L) increased signifi-
cantly during the first three visits, reaching a peak (11.5%,
33.8%, and 60.0%, respectively) on day 90 and remained
unchanged afterwards (55.6%, 48.6%, and 43.7% for visits 5
to 7, respectively; Table IV).
This study was planned as a long-term (18-month)
follow-up of patients with DVT, together with the ambu-
latory treatment option. Evaluation of patients for post-
thrombophlebitic syndrome (CEAP) during the last three
visits (months 6, 12, and 18) revealed edema as the most
frequent patient complaint during the last three visits, with
a tendency to increase to 42.6% of all patients during the
last visit (P  .248). Hyperpigmentation was evident in
10.8% of patients at visit 7 at 18 months. There were no
ulcerations at visits 5 and 6 and only one patient with active
ulceration at visit 7.
The incidence of pulmonary embolus (confirmed by
computerized tomography angiography in symptomatic
patients), recurrence, and postthrombotic syndrome were
the main efficacy measures, and bleeding was the primary
safety measure. Accordingly, recurrence was observed in
eight patients (3.3%) during the treatment period, severe
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in one patient (0.4%), and pulmonary embolus developed
in a patient (0.4%) whose INR level was 3.65 at the time of
the diagnosis. Heparin-induced thrombocytopenia (plate-
let counts on days 0, 10, and 30 were 385, 333, and 86
K/mm3, respectively) occurred in one patient (0.4%).
Safety. The initial increase determined in safety pa-
rameters, including ALT, AST, and CK levels, were fol-
lowed by normalization during the course of the study.
AST (25.5 18.6 vs 33.6 37.2 IU/L; P .01) and ALT
(26.7 24.5 vs 43.7 50.3 IU/L; P .001) levels in visit
Table III. Distribution of veins (%) according to recanaliz
Type of vein No.
Visit 1 (n  250) day 0
Visit 4 (n
m
Recanalization ratio Recanali
Occl 50% 50% Open Occl 50%
Involving the iliofemoral vein segment without caudad involveme
Common iliac 67 86.6 11.9 1.5 0 4.5 11.9
External iliac 33 93.9 6.1 0 0 12.1 36.4
Above knee but below the common femoral vein
Common femoral 61 80.3 19.7 0 0 9.8 26.2
Femoral 51 88.2 11.8 0 0 13.7 43.1
Below knee
Popliteal 29 82.8 10.3 6.9 0 13.8 27.6
Tibioperoneal 3 100 0 0 0 66.7 33.3
Fig 2. Complete recanalization ratios for iliofemoral (n  67),
external iliac (n  33), common femoral (n  61), femoral (n 
51), and popliteal veins (n  29) specific to 3, 12, and 18 months
of follow-up. *P  .001 compared with scores obtained at the
previous visit.2, and ALP levels (117.5  80.1 vs 104.5  70.1 IU/L;P  .01) in visit 3, were significantly higher than baseline
values, whereas they were normalized to initial levels at the
next visit (P .001 for each). No bleeding was determined
in 86.7% of patients. Minor and major bleeding rates were
12.2% and 1.6%, respectively. Patients with major bleeding
included decrease in hemoglobin in two on day 10, intra-
cranial bleeding in one on day 30, and menorrhagia requir-
ing hysterectomy in one during the 18th month. The
patient with intracranial bleeding had undergone a menin-
gioma operation 3.5 months before inclusion. Warfarin use
caused a subdural hematoma and minor hemiparesis to
develop, from which the patient recovered completely. The
patient with menorrhagia under oral anticoagulant treat-
ment underwent a hysterectomy. Of three patients diag-
ratios during the study period
7) 3rd Visit 6 (n  160) 12th
month
Visit 7 (n153) 18th
month
ratio Recanalization ratio Recanalization ratio
0% Open Occl 50% 50% Open Occl 50% 50% Open
.5 76.1 3 4.5 11.9 80.6 1.5 4.5 7.5 86.5
.2 36.3 6.1 12.1 27.3 54.5 9.1 18.2 21.2 51.5
.1 45.9 1.6 14.8 21.3 62.3 1.6 11.5 16.4 70.5
.6 17.6 9.8 15.6 37.3 37.3 3.9 17.7 39.2 39.2
.1 34.5 10.3 17.2 17.2 55.3 3.4 13.8 37.9 44.9
0 33.3 0 0 66.7 33.3 33.3 0 33.4
Fig 3. Evaluation of symptom incidence (%) of patients for pain,
edema, and tenderness during the course of the treatment. *P 
.05 and **P  .001 compared with incidence at the previous visit.
P  .001 compared with pretreatment incidence.ation
 17
onth
zation
5
nt
7
15
18
25
24nosed with major bleedings, two recovered with conserva-
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65 (9.9%) adverse events occurred that led to 11 deaths,
but no deaths were related to the study medications; of
these, only 2 events were defined as serious adverse events
but neither resulted in death.
DISCUSSION
LMWHs administered subcutaneously once or twice
daily have been reported as being as safe and efficacious as
intravenous UFH in the treatment of venous thromboem-
Fig 4. Comparison of pretreatment and posttreatment period in
terms of average difference in leg circumference (cm) of normal
and diseased leg measured at the calf (below the tibial tuberosity)
and at the middle thigh regions. *P  .05, **P  .01, and ***P 
.001 compared with scores obtained at the previous visit. P 
.001 compared with pretreatment scores.
Table IV. Alterations in the patient population with
normal leg circumference and D-dimer values during the
follow-up
Variable
Patients, %
pretreatment Posttreatment
(Day 0) (Day 30) (Day 90) (18 mon)
1.5 cm difference
in the
circumferences
of the legs
Calf region 35.6 . . . 90.7a 86.3a
Mid-thigh region 46.6 . . . 89.0a 89.7a
Normal D-dimer
values 6.3 33.8b 60.0b 43.7b
aP  .001 compared with pretreatment incidence of having 1.5 cm
difference in the circumferences of the legs.
bP  .01 compared with pretreatment incidence of having normal D-dimer
values.bolism (VTE) in large, well-established, prospective, mul-ticenter trials.3,7-9,27,28 VTE treatment was associated with
a significant reduction in the incidence of symptoms, cir-
cumference of the thrombotic leg, D-dimer scores, and
marked improvement of recanalization ratios for occluded
veins.
Although classical anticoagulant therapy has been doc-
umented to have low efficacy in recanalization of the il-
iofemoral vein, our results concerning early obtainment
and followingmaintenance of complete recanalization ratio
in the iliofemoral vein by means of enoxaparin plus warfarin
therapy accompanied with graduated compression stock-
ings seems promising.29,30 However, the possible role of a
high prevalence of provoked DVT among our patients in
this success needs further clarification.
In contrast to past studies29,30 that have reported fre-
quent bleeding complications associated with use of enox-
aparin combined with warfarin, bleeding complications
seem to be bypassed with enoxaparin plus warfarin treat-
ment in the present study: major bleeding was experienced
only in 1.6% of our patients, including decrease in hemo-
globin (n  2), intracranial bleeding (n  1), and menor-
rhagia requiring hysterectomy (n  1).
During the past few years, most studies have demon-
strated that the effectiveness and the safety of vitamin K
antagonist therapy depends on maintaining the INRwithin
the therapeutic range.31 Therefore, to efficiently manage
patients with VTE (prevention of recurrence without in-
creasing the risk of bleeding), recommendations are that a
therapeutic range of 2.0 to 3.0 be obtained for INR.31 In
fact, our INR evaluations showed that enoxaparin and
warfarin increased INR significantly during a 5- to 7-day
period, but keeping INR at these levels seems not to be
Fig 5. Percentage of patients with subtherapeutic international
normalized ratio (INR)2 or3 with respect to the first 90 days.possible after day 15.
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enoxaparin during the first 10 days of DVT occurrence has
a good outcome concerning recanalizations of occluded
veins for the 3-month follow-up, failure of warfarin in
keeping INR within effective limits seems to be evident
from the first 3 months of long-term follow-up. Failure in
keeping INR within desired limits seems not to be reflected
in terms of expected bleeding complications in our study
during the 18-month follow-up. However, lack of unfavor-
able bleeding complications, despite ongoing abnormali-
ties in INR levels during 18 months, may not justify the
likelihood of bleeding risk in the prolonged term.
Determination of D-dimer has been considered among
the strategies that have been developed and published in
the last few years as an alternative to clinical examination
and imaging methods that have a low sensitivity for isolated
distal DVT, especially those of the calf veins.32,33 In this
vein, an increase in the number of patients with D-dimer
concentrations in the normal range during 3-month ther-
apy in the present study seems to indicate the low risk of
recurrence associated with normalization of D-dimer val-
ues, because recurrence was observed in only eight patients
(3.25%) after completion of the 18-month follow-up.
However, because several controlled trials have shown that
the incidence of recurrence is greater for idiopathic VTE,31
conclusions concerning the exact relation of D-dimer levels
to possible recurrence risk must be cautiously drawn for a
population such as in our study, which was composed
mainly of provoked DVT. Despite not being evaluated in
the present study, factors such as liver disease, pregnancy,
eclampsia, heart disease, advanced age, high levels of rheu-
matoid factor, and lipemia that have been associated with
an elevation in D-dimer levels may also be evident in the
present study, whereas we sought to determine the de-
crease or normalization of D-dimer levels in response to the
treatment rather than factors leading to its elevation as a
follow-up measure for thrombus burden or recurrent VTE
risk.
Because the diagnostic workup of patients with sus-
pected DVT is far from consensus, data concerning advan-
tages and disadvantages of different methodologies per-
formed at different hospitals are more or less available.32-35
In accordance with the documented benefits of managing
ambulatory treatment on an outpatient basis in terms of
effectiveness, safety, and practicability of this procedure, as
well as cost-effectiveness by saving the costs of inpatient
treatment,36 ambulatory outpatient treatment lasting 18
months seems to be more effective for proximal DVT than
distal DVT according to the DUS imaging in our study.
Furthermore, because superiority of thrombolytic treat-
ment has been mainly based on the successful results ob-
tained for iliofemoral DVT,37 undeniable success of con-
ventional therapy plus graduated compression stockings in
recanalization of iliofemoral veins reported in our study
seems quite meaningful.
Data concerning superiority of thrombolytic treatment
vs conservative treatment19 rely on reports published 25 to
30 years ago, when patients were usually treated with UFHin the hospital without compression stockings, enough
ambulation, and optimal INR follow-up.38,39 Therefore,
when compared with the old reports38,39 on a conservative
approach in DVT treatment, the main differences in our
study were the administration of once-daily LMWH (enox-
aparin) therapy, class II compression stockings for at least 1
year, intense ambulation at home, and the predominance of
provoked type DVT among our study population. Accord-
ingly, as the subjects of the most recent long-term
follow-up of DVT treatment, our patients seem to repre-
sent a more convenient population for comparison with
thrombolytic treatment.
Major limitations of the present study relate to its
design as an open-label, single-arm clinical trial rather than
a randomized active-controlled study leading to subjective
end points regarding comparison with thrombolytic treat-
ment of clot removal method among patients diagnosed
mainly with provoked type DVT. Moreover, although use
of DUS scanning, which is not a validated method to
evaluate degree of obstruction in the iliocaval segment, is
another limitation of the present study, there is a gradual
increase in the number of studies using DUS scanning in
relation to the invasive nature of venography associated
with relatively higher morbidity rates. We thought it would
be acceptable to assess the development of PTSwith C-class
of the CEAP classification together with clinical and DUS
examinations. However, this is a limitation of the study,
because we reported only the “C” of the CEAP classifica-
tion rather than all parts to describe the status of the limbs.
CONCLUSIONS
Ambulatory treatment with enoxaparin plus warfarin
accompanied with graduated compression stockings seems
to be effective in symptomatic healing as well as clinical
improvement by reducing thrombus formation and orga-
nization at all levels of the lower limb venous system in
DVT, without a significant major bleeding risk. Conven-
tional conservative treatment having level of evidence 1A
may seem to have comparable and even preferable results in
terms of better cost-effectiveness to thrombolytic treat-
ment recommended in recent studies, especially for iliofem-
oral DVT. Further randomized controlled trials are needed
to confirm these conclusions.
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Much high-quality evidence exists for the effective therapy
for acute deep vein thrombosis (DVT); namely, rapid and therapeutic
low-molecular-weight heparin (LMWH) anticoagulation, followed
by transition to a vitamin K antagonist, early application of compres-
sion therapy, and ambulation. Moreover, markers for ceasing or
continuing oral anticoagulation are now coming to light, such as
D-dimer and follow-up duplex ultrasound imaging.1 The trials for
which the data are based on have generally captured early efficacy and
safety, such as recurrent venous thromboembolism (VTE), bleeding
rates, and tolerance. Fewer studies have captured the long-term results
of the evidence-based therapies for DVT, but these data are needed,
given the commonality of DVT occurrence and its primary nonfatal
sequelae, post thrombotic syndrome (PTS).
The current study by Kurtoglu et al is novel and important,
not because it confirms that LMWH transitioning to a vitamin K
antagonist is safe and effective but rather because it brings to light
that well-applied, comprehensive, multimodality therapy is highly
effective for preventing VTE recurrence and preventing major post
thrombotic morbidity. Unlike many trials that evaluate a single
variable intervention, this trial evaluated the “whole package” of
evidence-based DVT treatment, with excellent patient follow-up.
This trial mimics, in part, several studies showing efficacy of
multimodality intensive diabetes therapy, although there was no
separate control group in the current study. The primary outcomesembolism rate, and 0.7% venous ulceration at 18 months. Safety
was also excellent, with a major bleeding rate of 1.6% and an
adverse event rate of about 10%. Both of these measures rival prior
larger trial end point efficacy. Not examined here is the likely cost
savings resulting from outpatient treatment as the primary mode,
thus eliminating the need for laboratory draws (activated partial
thromboplastin time) and an inpatient stay.
A primary risk for PTS is recurrent DVT and a greater extent of
DVT. Although the incidence of C4 through C6 disease (more
severe PTS) was low in this study, it should be known that the best
measure for PTS is the Villalta score, and thus this study may
underestimate some of the disability related to the patient’s DVT.2
Regardless, the low rate of PTS may be because therapeutic anti-
coagulation compliance rates were high (80%), and those pa-
tients with an unprovoked DVT were very low; both of these
factors are associated with increased risk of PTS.3 Nonetheless, the
large number of patients in this study with an iliofemoral DVT, a
significant risk factor for PTS, underscores the effectiveness of this
multimodality therapy; that is, most of these iliofemoral segments
recanalized over time. As stated by the authors, these findings
challenge the wide application of expensive and invasive pharma-
comechanical therapy for all DVT patients. Similarly, Hull et al4
recently reported that prolonged LMWH therapy was associated
with a significant reduction in PTS compared with standard anti-
coagulation.
